Form 4 · Statement of Changes in Beneficial Ownership · Filed 2026-08-06
Mahon Paul A Files United Therapeutics (UTHR) Form 4 - August 06, 2026
Mahon Paul A traded 16.6K UTHR shares worth $5.5M in this Form 4 filing, reported to the SEC on 2026-08-06.
- Insider
- Mahon Paul A
- Issuer
- United Therapeutics Corporation UTHR · NASDAQ
- Filed
- Period
- 2026-08-06
- Accession
- 0001231589-26-000017
- Source
- Official filing on sec.gov ↗
Transactions (10)
| Insider | Date | Type | Shares | Price | Value | Own |
|---|---|---|---|---|---|---|
| Mahon Paul A | 2026-08-06 | Buy | 8.3K | $146.03 | $1.2M | Direct |
| Mahon Paul A | 2026-08-06 | Sell | 760 | $512.92 | $389.8K | Direct |
| Mahon Paul A | 2026-08-06 | Sell | 1.8K | $514.82 | $924.1K | Direct |
| Mahon Paul A | 2026-08-06 | Sell | 1.4K | $515.93 | $701.7K | Direct |
| Mahon Paul A | 2026-08-06 | Sell | 1.6K | $516.93 | $835.9K | Direct |
| Mahon Paul A | 2026-08-06 | Sell | 780 | $517.94 | $404.0K | Direct |
| Mahon Paul A | 2026-08-06 | Sell | 360 | $518.82 | $186.8K | Direct |
| Mahon Paul A | 2026-08-06 | Sell | 1.3K | $521.50 | $682.1K | Direct |
| Mahon Paul A | 2026-08-06 | Sell | 320 | $522.39 | $167.2K | Direct |
| Net change | 0 | −$3.1M | ||||
About United Therapeutics Corporation
United Therapeutics Corporation is a biotechnology company engaged in the development and commercialization of innovative pharmaceutical products. Primarily focusing on therapies to address unmet medical needs for chronic and life-threatening conditions, United Therapeutics is notable for its contributions in the field of pulmonary arterial hypertension (PAH). The company offers a portfolio of products that include both oral and inhaled treatments, such as Remodulin and Tyvaso, providing critical care solutions that significantly improve patients' quality of life. Additionally, they are investing in innovative technologies such as organ manufacturing and regenerative medicine, showcasing a commitment to future medical advances. Headquartered in Silver Spring, Maryland, United Therapeutics operates across various stages of drug research, from clinical trials to post-market analysis. As a key player in the biotechnology industry, the company holds an influential position, contributing to significant advancements in therapeutic solutions and reinforcing its role in the healthcare market by addressing complex medical challenges and patient needs effectively.
Track UTHR insider activity
Get alerted when United Therapeutics Corporation executives buy or sell their shares.